Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease.
Activities of Daily Living
Adaptation, Psychological
Adolescent
Adult
Aged
Aged, 80 and over
Crohn Disease
/ epidemiology
Female
Humans
Italy
Linear Models
Male
Middle Aged
Patient Satisfaction
/ statistics & numerical data
Prospective Studies
Psychiatric Status Rating Scales
Quality of Life
Stress, Psychological
/ epidemiology
Work Capacity Evaluation
Young Adult
Crohn’s disease
Patient’s concerns
Quality of life
Treatment adherence and satisfaction
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
20
09
2018
revised:
13
12
2018
accepted:
22
12
2018
pubmed:
28
1
2019
medline:
30
1
2020
entrez:
28
1
2019
Statut:
ppublish
Résumé
The SOLE study was conducted on a large cohort of Italian patients with moderate-severe Crohn's disease (CD) to assess epidemiological and disease characteristics and their correlation with disease-related worries, treatment satisfaction and adherence, workability. The following tools were used over 12 months to assess: Results were correlated with demographic and clinical variables with linear regression models. 552 patients with active CD (51% men) were recruited. Higher worries were having an ostomy bag and undergoing surgery. Variables associated with a higher RFIPC score included female sex, higher disease activity, lower treatment adherence (p < 0.001), previous surgical treatments (p = 0.003). 60% of patients claimed difficulties with activities of daily living. Lower VAS scores were reported by patients with disease duration >6years; treatment satisfaction/adherence was higher with anti-TNF-α treatment. Decreased hospitalizations during follow-up and improved workability/daily activities occurred with adalimumab, infliximab, azathioprine (p < 0.001). Worries included having an ostomy bag, undergoing surgery, developing cancer: conditions significantly associated with worsened disease activity and low treatment adherence. Higher treatment adherence scores/greater workability improvements were observed in patients treated with anti-TNF-α agents.
Sections du résumé
BACKGROUND-AIMS
The SOLE study was conducted on a large cohort of Italian patients with moderate-severe Crohn's disease (CD) to assess epidemiological and disease characteristics and their correlation with disease-related worries, treatment satisfaction and adherence, workability.
METHODS
The following tools were used over 12 months to assess: Results were correlated with demographic and clinical variables with linear regression models.
RESULTS
552 patients with active CD (51% men) were recruited. Higher worries were having an ostomy bag and undergoing surgery. Variables associated with a higher RFIPC score included female sex, higher disease activity, lower treatment adherence (p < 0.001), previous surgical treatments (p = 0.003). 60% of patients claimed difficulties with activities of daily living. Lower VAS scores were reported by patients with disease duration >6years; treatment satisfaction/adherence was higher with anti-TNF-α treatment. Decreased hospitalizations during follow-up and improved workability/daily activities occurred with adalimumab, infliximab, azathioprine (p < 0.001).
CONCLUSION
Worries included having an ostomy bag, undergoing surgery, developing cancer: conditions significantly associated with worsened disease activity and low treatment adherence. Higher treatment adherence scores/greater workability improvements were observed in patients treated with anti-TNF-α agents.
Identifiants
pubmed: 30685416
pii: S1590-8658(18)31447-6
doi: 10.1016/j.dld.2018.12.019
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
804-811Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.